Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] jumped around 0.2 points on Monday, while shares priced at $18.06 at the close of the session, up 1.12%.
Teva- Pharmaceutical Industries Ltd. ADR stock is now 0.28% up from its year-to-date (YTD) trading value. TEVA Stock saw the intraday high of $18.278 and lowest of $18.0 per share. The company’s 52-week high price is 22.80, which means current price is +44.89% above from all time high which was touched on 01/28/25.
Compared to the average trading volume of 11.26M shares, TEVA reached a trading volume of 11317212 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Teva- Pharmaceutical Industries Ltd. ADR [TEVA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TEVA shares is $24.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TEVA stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Teva- Pharmaceutical Industries Ltd. ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 06, 2025. While these analysts kept the previous recommendation, Truist raised their target price to Buy. The new note on the price target was released on May 28, 2025, representing the official price target for Teva- Pharmaceutical Industries Ltd. ADR stock. Previously, the target price had yet another raise to $23, while JP Morgan analysts kept a Overweight rating on TEVA stock.
The Price to Book ratio for the last quarter was 3.03, with the Price to Cash per share for the same quarter was set at 1.88. Price to Free Cash Flow for TEVA in the course of the last twelve months was 17.43 with Quick ratio for the last quarter at 0.77.
How has TEVA stock performed recently?
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.99. With this latest performance, TEVA shares gained by 12.45% in over the last four-week period, additionally plugging by 11.14% over the last 6 months – not to mention a drop of -18.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TEVA stock in for the last two-week period is set at 70.24, with the RSI for the last a single of trading hit 0.46, and the three-weeks RSI is set at 0.48 for Teva- Pharmaceutical Industries Ltd. ADR [TEVA]. The present Moving Average for the last 50 days of trading for this stock 16.72, while it was recorded at 17.45 for the last single week of trading, and 17.21 for the last 200 days.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Teva- Pharmaceutical Industries Ltd. ADR [TEVA] shares currently have an operating margin of 21.05% and a Gross Margin at 49.55%. Teva- Pharmaceutical Industries Ltd. ADR’s Net Margin is presently recorded at -0.91%.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Capital Structure & Debt Analysis
According to recent financial data for Teva- Pharmaceutical Industries Ltd. ADR. ( TEVA), the Return on Equity (ROE) stands at -2.31%, reflecting a slight decline for investors. The Return on Assets (ROA) is -0.37%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Teva- Pharmaceutical Industries Ltd. ADR’s Return on Invested Capital (ROIC) is -0.64%, showcasing its effectiveness in deploying capital for earnings.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Efficiency & Liquidity Metrics
Based on Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) latest financial statements, the Debt-to-Equity Ratio is 2.57%, indicating its reliance on debt financing relative to shareholder equity.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Teva- Pharmaceutical Industries Ltd. ADR. (TEVA) effectively leverages its workforce, generating an average of -$4206.32 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.06% and a Quick Ratio of 0.77%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Teva- Pharmaceutical Industries Ltd. ADR [TEVA]
With the latest financial reports released by the company, Teva- Pharmaceutical Industries Ltd. ADR posted 0.69/share EPS, while the average EPS was predicted by analysts to be reported at 0.66/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.03. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TEVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Teva- Pharmaceutical Industries Ltd. ADR go to 7.20%.
Insider trade positions for Teva- Pharmaceutical Industries Ltd. ADR [TEVA]
There are presently around $66.20%, or 66.20%% of TEVA stock, in the hands of institutional investors. The top three institutional holders of TEVA stocks are: BLACKROCK INC. with ownership of 42.99 million shares, which is approximately 3.7942%. FMR LLC, holding 41.98 million shares of the stock with an approximate value of $$682.15 million in TEVA stocks shares; and FMR LLC, currently with $$590.36 million in TEVA stock with ownership which is approximately 3.2065%.
